DUBLIN–(BUSINESS WIRE)–The “Ocular Drug Delivery Market Forecast to 2028 – COVID-19 Impact and Global Analysis by Technology, Formulation Type, Disease Type, End User and Geography” report has been added to ResearchAndMarkets.com’s offering.
The ocular drug delivery market was valued at US$ 16,404.32 million in 2021 and is projected to reach US$ 27,016.20 million by 2028; it is expected to grow at a CAGR of 7.4 % from 2021 to 2028.
The growth of the ocular drug delivery market is attributed to factors such as growing prevalence of eye disorders and rising research on ocular drug delivery. However, the market is likely to get impacted by several disadvantages associated with ocular drug delivery.
For instance, ocular drug delivery systems with eye drops led to extensive loss of the drug due to rapid elimination from the eye. Similarly, topical delivery of ocular drugs is unable to reach the posterior segment of the eye.
An ocular drug delivery system (ODDS) is a dosage form, vehicle, or system intended to instill, administer, or deliver drug/medicine to the eye against any ailment or disorder involving or affecting vision. It ranges from simple sterile eye drop for the ocular surface to complex implants for intraocular tissue. Ocular drug formulations are primarily liquid forms, such as solutions, suspensions, and emulsions for treating anterior eye segment diseases.
These formulations can be available in the form of advanced drug delivery systems like in-situ gel, microemulsion, nanoparticle, liposome, iontophoresis, nanosuspension, and ocular inserts.
Key Market Dynamics
Key Market Drivers
- Growing Prevalence of Eye Disorders
- Rising Research on Ocular Drug Delivery
Market Restraints
- Disadvantages Associated with Ocular Drug Delivery
Market Opportunities
- Increasing Awareness About Vision Care
Future Trends
- Development of Innovative Products
Companies Mentioned
- AbbVie Inc.
- Bausch Health Companies Inc.
- Taiwan Liposome Company, Ltd.
- Ocular Therapeutix, Inc.
- GRAYBUG VISION, INC.
- Alimera Sciences, Inc.
- Envisia Therapeutics
- Novartis AG
- EYEGATE PHARMACEUTICALS, INC
- Clearside Biomedical, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/i2sm2z
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
This is a syndicated feed and is brought to you in partnership with Business Wire. Aarogya Khabar and Trade News Network are not responsible for any claims made in this story.